Company provides additional management updates FREMONT, Calif. / Jul 08, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company’s strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025. The approved proposals included the issuance of equity as a form of payment... Read More

Breakthrough Findings to be Reported Later this Year and Applied to Upcoming Phase I Clinical Trial FREMONT, Calif. / Jun 25, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical... Read More

FREMONT, Calif. / Jun 24, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless... Read More

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT FREMONT, Calif. / May 15, 2025 / Business Wire / Tivic Health ® Systems, Inc . (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. “This is a defining time for the company. During the quarter... Read More

FREMONT, Calif. / May 14, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application,... Read More

New patent protects methods for increasing efficacy via personalization of stimulation parameters and electrode positioning FREMONT, Calif. / May 13, 2025 / Business Wire / Tivic Health ® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent... Read More

FREMONT, Calif. / May 09, 2025 / Business Wire / Tivic Health® Systems, Inc . (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details:... Read More

Senior Level Meetings Included Discussion of Tivic’s TLR5 and Vagus Nerve Stimulation Programs FREMONT, Calif. / Apr 22, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and... Read More

FREMONT, Calif. / Apr 15, 2025 / Business Wire / Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor... Read More

FREMONT, Calif. / Apr 10, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health’s common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol... Read More

Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT FREMONT, Calif. / Mar 21, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company’s operations. “The important strategic... Read More

FREMONT, Calif. / Mar 13, 2025 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET.... Read More

Advances Tivic’s Development of Non-Invasive VNS Devices Aimed at Treating Inflammatory, Cardiac and Neurologic Disorders FREMONT, Calif. / Mar 06, 2025 / Business Wire / Tivic Health ® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation’s impact on autonomic nervous system... Read More

FREMONT, Calif. / Mar 05, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic Health” or the “Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company’s issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price... Read More

Patent based on state-of-the-art science of vagus nerve stimulation approach shows greater effect from personalization of treatment FREMONT, Calif. / Mar 03, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with... Read More

Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma FREMONT, Calif. / Feb 24, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has... Read More

Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. FREMONT, Calif. / Feb 12, 2025 / Business Wire / Tivic Health Systems, Inc. , (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like... Read More

Provides updates on vagus nerve stimulation (VNS) program and expectations for 2025 FREMONT, Calif. / Dec 23, 2024 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I’d like to take this opportunity to recap some... Read More

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT FREMONT, Calif. / Nov 14, 2024 / Business Wire / Tivic Health ® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS)... Read More

FREMONT, Calif. / Nov 14, 2024 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The... Read More

Patents cover methods used to identify key treatment points and dynamically personalize simulation FREMONT, Calif. / Nov 12, 2024 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The Company believes... Read More

Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST FREMONT, Calif. / Nov 07, 2024 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST /... Read More

FREMONT, Calif. / Oct 29, 2024 / Business Wire / Tivic Health ® Systems, Inc . (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation device. The study, being run by The Feinstein Institute of Bioelectronic Medicine, will... Read More

Presentation will highlight Tivic Health’s recent advancements in vagus nerve stimulation SAN FRANCISCO / Oct 24, 2024 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst’s presentation, Tuesday, October... Read More

SAN FRANCISCO / Sep 18, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes’ Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation (“ncVNS”) approach. This clinical research... Read More

Partners with leading growth strategy firm, Fletcher Spaght SAN FRANCISCO / Sep 17, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght (“FSI”), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive... Read More

Kimberly Bambach, Ms. Wolf’s predecessor, continues with Tivic as advisor focused on strategic transactions and special projects SAN FRANCISCO / Sep 13, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company,... Read More

SAN FRANCISCO / Aug 14, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter 2024 financial results and discussed growth strategies based on its investments in vagus nerve stimulation ("VNS"). “This quarter is the start of a potentially transformational period for Tivic. We announced the... Read More

SAN FRANCISCO / Aug 06, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future... Read More

SAN FRANCISCO / Aug 02, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the Virtual Annual General Meeting of Shareholders will be held on Friday, August 9, 2024 at 10:00 a.m., Pacific Time. The Company has adopted a virtual format for our Annual Meeting to provide a healthy, consistent, and... Read More

Three New Patents Granted in the US and Europe SAN FRANCISCO / Jul 23, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO): US Patent 12,011,592 and European Patent... Read More

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health’s Governance Team SAN FRANCISCO / Jun 18, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served... Read More

SAN FRANCISCO / May 22, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncVNS”). The company has entered into a collaboration agreement with The Feinstein Institutes for... Read More

SAN FRANCISCO / May 15, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter 2024 financial results with discussion of subsequent events. "Q1 2024 and the weeks thereafter represent a critical juncture in Tivic's advancement in the bioelectronics field. We increased gross profit and reduced... Read More

SAN FRANCISCO / May 13, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded conference call and webcast on Wednesday, May 15 th at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016... Read More

SAN FRANCISCO / May 13, 2024 / Business Wire / Tivic Health ® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the closing of its previously announced public offering of an aggregate of 4,710,000 shares of its common stock, Series A warrants to purchase up to 4,710,000 shares of common stock and Series B warrants to purchase up to 7,065,000... Read More

SAN FRANCISCO / May 09, 2024 / Business Wire / Tivic Health ® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its public offering of an aggregate of 4,710,000 shares of its common stock, Series A warrants to purchase up to 4,710,000 shares of common stock and Series B warrants to purchase up to 7,065,000 shares of common... Read More

SAN FRANCISCO / May 08, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today the final results of their pilot research study with The Feinstein Institutes for Medical Research at Northwell Health. Through this collaboration, Tivic Health has confirmed the effectiveness of its patent-pending... Read More

SAN FRANCISCO / Mar 25, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023. Tivic’s commercial platform is a handheld design that interfaces non-invasively with the trigeminal, sympathetic, and other facial and cranial nerve structures. This... Read More

SAN FRANCISCO / Mar 19, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”) (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International:... Read More

SAN FRANCISCO / Feb 21, 2024 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed. VNS is a growing market that is part of the $8.3B global neurostimulation market, which has a... Read More

SAN FRANCISCO / Jan 30, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has entered a limited exclusive distribution agreement with one of the Top 10 Medical Equipment Distributors and Suppliers in the nation. Under the terms of the agreement, the new Distributor will have certain exclusive... Read More

SAN FRANCISCO / Jan 08, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today the launch of the second generation of Tivic ClearUP. The new and improved Tivic ClearUP 2.0, now with a new chip for power management for faster charge and longer battery life, is available starting today on... Read More

71% Gross Profit Increase; 30% Decrease in Operating Expenses SAN FRANCISCO / Nov 14, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”). Third Quarter 2023 Financial Highlights Revenue for Q3 2023 was $282 thousand, compared to... Read More

SAN FRANCISCO / Nov 07, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter 2023 via pre-recorded conference call and webcast on Tuesday, November 14 th , 2023 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062... Read More

New Healthcare Provider Program Set to Educate and Drive Patient Awareness of ClearUP SAN FRANCISCO / Sep 26, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has signed an agreement with InStep Health ® to introduce the Company’s bioelectronic sinus device, ClearUP ® , to over 2,500 healthcare... Read More

SAN FRANCISCO / Sep 20, 2023 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic” or the “Company”), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) informing Tivic that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule... Read More

SAN FRANCISCO / Aug 28, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has entered into a non-exclusive agreement with AmerisourceBergen, soon to be Cencora, to make Tivic’s products available on AmerisourceBergen’s third-party marketplace. Tivic’s patented ClearUP... Read More

SAN FRANCISCO / Aug 22, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC) (“Tivic” or the “Company), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today that its Board of Directors has declared a 1-for-100 reverse stock split of the company’s issued and outstanding shares of common stock. The reverse stock split will become effective... Read More

SAN FRANCISCO / Aug 16, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board (“IRB”) and has initiated study recruitment and enrollment for its... Read More

SAN FRANCISCO / Aug 14, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 (“Q2 2023”). Second Quarter 2023 Financial Summary Gross profit of 37.5% in the second quarter of 2023, compared to 23.4% in the second quarter of 2022, on total... Read More

SAN FRANCISCO / Aug 07, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter of 2023 via pre-recorded conference call and webcast on Monday, August 14 th , 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll-Free: 877-545-0523... Read More

SAN FRANCISCO / Aug 06, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 33,173,000 shares of its common stock at a public offering price of $0.041 per share. Gross proceeds from the offering are expected to be approximately $1.4... Read More

SAN FRANCISCO / Aug 04, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it intends to offer and sell shares of its common stock in a public offering. All of the shares of common stock are being offered by Tivic. Tivic intends to use the net proceeds of the offering, if any, for working... Read More

SAN FRANCISCO / Jul 31, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the U.S. Patent and Trademark Office has issued its sixth patent for its bioelectronic platform, expanding the Company’s intellectual property to include the proprietary contacts, conductive circuitry design, and algorithms to... Read More

Tivic Health CEO Provides Additional Information Regarding the Company’s Current Report on Form 8-K SAN FRANCISCO / Jul 28, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today issued the following letter from the CEO, Jennifer Ernst, providing additional information regarding the company’s current report on Form 8-K... Read More

SAN FRANCISCO / Jul 17, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 51,250,000 shares of its common stock at a public offering price of $0.04 per share. Gross proceeds from the offering are expected to be approximately $2.1... Read More

SAN FRANCISCO / Jul 11, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has completed a full internal assessment of its supply chain and has established that its ClearUP product is Halal compliant. Of all the industries the American Halal Foundation (AHF) serves, there is probably none... Read More

SAN FRANCISCO / Jul 10, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 32,500,000 shares of its common stock at a public offering price of $0.055 per share. Gross proceeds from the offering are expected to be approximately $1.8... Read More

SAN FRANCISCO / Jul 07, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it intends to offer and sell shares of its common stock in a public offering. All of the shares of common stock are being offered by Tivic. Tivic intends to use the net proceeds of the offering, if any, for working... Read More

SAN FRANCISCO / Jun 27, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has entered into a non-exclusive distribution agreement with Cardinal Health (RGH Enterprises) for Tivic’s products. Cardinal Health is a leading distributor and manufacturer of medical products and... Read More

SAN FRANCISCO / Jun 15, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the company is expanding its target market for ClearUP to the vast population of consumers with allergy and congestion-related issues who are deprived of sleep, exercise, and concentration. A recent Tivic study with over 2,000... Read More

Tivic urges shareholders of record as of April 13, 2023, to vote their shares. SAN FRANCISCO / Jun 09, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on Tuesday, June 6, 2023, was partially adjourned... Read More

Gross Profit Increase by 61.3%; extends innovation pipeline to include vagus nerve stimulation. SAN FRANCISCO / May 15, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce its financial results for the first quarter of 2023 ended March 31, 2023 (“Q1 2023”). First Quarter 2023 Financial Summary Gross... Read More

SAN FRANCISCO / May 11, 2023 / Business Wire / Tivic Health ® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter 2023 via a pre-recorded conference call and webcast on Monday, May 15 th , 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll Free: 877-545-0523... Read More

SAN FRANCISCO / May 08, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has launched a B2B portal to support its increasing demand for commercial ordering of its doctor recommended and FDA-approved bioelectronic sinus device, ClearUP. This portal is available to pharmacy groups and healthcare... Read More

SAN FRANCISCO / May 01, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen... Read More

Opportunity for Bioelectronic Medicine to Reduce Dependence on Opioids SAN FRANCISCO / Apr 19, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has expanded its post-operative pain clinical study to include Otolaryngology and Facial Plastic Surgery patients. This study aims to investigate the... Read More

SAN FRANCISCO & MANHASSET, N.Y. / Apr 13, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced a research collaboration with The Feinstein Institutes for Medical Research to conduct a pilot clinical study that will test a novel non-invasive bioelectronic device approach for vagus nerve... Read More

SAN FRANCISCO / Apr 11, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it has filed its first patent in Vagus Nerve Stimulation with the U.S. Patent Office (USPTO), expanding its intellectual property portfolio into new clinical targets. Tivic’s prior patents and... Read More

SAN FRANCISCO / Mar 31, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2022. Year over Year Highlights 46% growth in revenue 114% growth in direct to consumer channels 9X improvement in gross margin Jennifer Ernst, CEO... Read More

SAN FRANCISCO / Mar 29, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first article inspection of Microart Services, Inc., one of two new partners announced in Q4 of 2022. The supplier qualification and successful first article... Read More

SAN FRANCISCO / Mar 24, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the year ended December 31, 2022, via pre-recorded conference call and webcast on Friday, March 31, 2023, at 1:30 pm PT / 4:30 pm ET. Teleconference Details:... Read More

SAN FRANCISCO / Mar 14, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first article inspection of ALOM, one of two new partners announced in Q4 of 2022. The supplier qualification and successful first article inspection help... Read More

SAN FRANCISCO / Mar 02, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, has been named to Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2023 in the Medical Device category. Tivic’s first commercial product, ClearUP, is an FDA approved and CE-Marked... Read More

SAN FRANCISCO / Feb 23, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has received recertification of ISO 13485, the international standard for medical device quality systems. The company also announced the recertification of ClearUP under the European Union Medical Device... Read More

SAN FRANCISCO / Feb 13, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC) (“Tivic” or the “Company), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the closing of its previously announced underwritten public offering of an aggregate of 20,000,000 shares of common stock at a public offering price of $0.25 per share, for aggregate... Read More

SAN FRANCISCO / Feb 08, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the pricing of an underwritten public offering of an aggregate of 20,000,000 shares of common stock. Each share is being sold to the public at a price of $0.25 per share, for aggregate gross proceeds of... Read More

SAN FRANCISCO / Jan 24, 2023 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that Global Health & Pharma (GHP) has named Tivic Health the Most Pioneering Bioelectronic Medicine Company of 2022. “Thank you to the editors at GHP for again recognizing the advantages and promise of... Read More